Work Here?
Overview
Enveda Biosciences uses machine learning, metabolomics, and robotics to explore the largely untapped natural world for drug discovery. Its main asset is a proprietary high-throughput platform that runs many experiments to generate a comprehensive dataset of small molecules, including their chemical structures, biological activity, and how they distribute in organs. This data helps identify potential drug leads quickly and supports partnerships with healthcare and pharmaceutical companies through collaborations and licensing of discoveries. Unlike many rivals, Enveda focuses on expanding knowledge of natural product chemistry beyond the small portion already known, aiming to accelerate the pace of drug discovery by systematically exploring natural chemical space and building a pipeline for its partners.
About Enveda
Industries
Data & Analytics
Robotics & Automation
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Series D
Total Funding
$534.8M
Headquarters
Boulder, Colorado
Founded
2019
People at Enveda
People at Enveda who can refer or advise you
Simplify's Take
What believers are saying
- ENV-294 achieved 85% EASI reduction in Phase 1b trials, showing durable disease modification[1]
- ENV-294 initiated Phase 2a trials in atopic dermatitis and asthma in December 2025[2]
- ENV-308 shows sustained appetite suppression preventing weight regain post-GLP-1 withdrawal[3]
What critics are saying
- ENV-294 may fail Phase 2 commercialization due to insufficient durability or scalability[4]
- Copycat competition from firms like Regeneron could erode market share within two years[5]
- FDA may reject due to small Phase 1b cohort and lack of diverse patient representation[6]
What makes Enveda unique
- Enveda uses AI to explore uncharted natural chemical space for drug discovery[1]
- Its platform enables high-throughput experiments creating comprehensive small molecule datasets[2]
- Targets a novel non-kinase inflammatory pathway distinct from JAK-STAT therapies[3]
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$534.8M
Above
Industry Average
Funded Over
10 Rounds
Industry standards
Benefits
Traditional or Roth 401k matching of 4% (100% of your contributions up to 4% of your annual compensation)
Medical, dental and vision insurance. 100% coverage of employee premiums and 33% coverage of dependents
Unlimited paid time off
Flexible work hours and paid parental leave
Company-wide weeklong break to recharge in addition to 8 observed holidays
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 2%2 year growth
↑ 0%Enveda raises $150M Series D, reaches unicorn status, enrolls first patient in clinical trials, and adds former Pfizer CSO Mikael Dolsten to board.
Enveda Biosciences, a Colorado biotech, has secured an additional $150 million for its I&I drug and a wide-ranging pipeline of preclinical assets. The company has grown from an initial $50k "pre, pre-seed" investment to $517 million in total funding, achieving unicorn status.
Enveda Biosciences raised $150 million in Series D funding, doubling its venture capital intake this year. The round was led by Premji Invest and included investors like Kinnevik and Lux Capital. Enveda has begun Phase 1b trials for its lead drug candidate in atopic dermatitis and plans to enter more drugs into human trials soon. The company aims to file investigational new drug applications for other programs over the next year.
AI is helping Corteva Agriscience dramatically accelerate the development of new crop protection products by modeling proteins and molecules with “unprecedented speed and accuracy,” an exec told a congressional subcommittee this morning. Speaking at a House Environment Subcommittee hearing on innovations in agrichemicals, Brian Lutz, PhD, VP agricultural solutions at Corteva, said AI had “revolutionized discovery by allowing us to trade randomness and chance for prediction, specificity and design.”. Predicting the structure of proteins in seconds
Enveda, a Boulder, CO-based biotechnology company empowering life’s chemistry to discover new medicines, received an investment from Sanofi, bringing the total of Series C funding to $150M
Enveda is Hiring for 8 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Enveda
Industries
Data & Analytics
Robotics & Automation
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Series D
Total Funding
$534.8M
Headquarters
Boulder, Colorado
Founded
2019
Enveda is Hiring for 8 Jobs on Simplify!
Find jobs on Simplify and start your career today